NCT05762003View on ClinicalTrials.gov

Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

CompletedOBSERVATIONAL

Enrollment

17,478

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Multiple Sclerosis

Interventions

DRUG

interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab

Administered as part of routine clinical practice.

Trial Locations (1)

12000

IMPULS Endowment Fund, Prague

All Listed Sponsors

lead

IMPULS Endowment Fund

OTHER

NCT05762003 - Czech Pharmaco-epidemiological Study on Disease Modifying Drugs | Biotech Hunter | Biotech Hunter